Wave Life Sciences Reports Q2 2026 Results: $490.6M Cash, Pipeline Advances in Obesity and AATD
WVE is trading near its 52-week low of $5.02 (9.8% above the low).
Summary
Wave Life Sciences posted Q2 2026 results with $490.6M in cash and a net loss of $69.4M. Key pipeline updates include the start of Phase 2a dosing for obesity drug WVE-007, an upcoming FDA meeting on accelerated approval for WVE-006, and a planned CTA for WVE-008.
Key Events · Earnings and Guidance · WVE
-
Q2 2026 Financial Results
Net loss of $69.4M on revenue of $2.3M; R&D expenses rose to $51.3M and G&A to $24.8M. Cash, equivalents, and marketable securities totaled $490.6M as of June 30, 2026, with expected runway into Q3 2028.
-
WVE-007 Phase 2a Dosing Underway
Dosing has begun in the Phase 2a multidose portion of the INLIGHT trial for WVE-007 in individuals with obesity (BMI 35-50 kg/m²). The trial will also inform potential in MASH, type 2 diabetes, and other cardiometabolic diseases.
-
FDA Meeting on WVE-006 Accelerated Approval
An FDA meeting is scheduled for end of summer 2026 to discuss a potential accelerated approval pathway for WVE-006 in AATD, following positive RestorAATion-2 data showing MZ-like phenotype restoration.
-
WVE-008 CTA Filing on Track
A Clinical Trial Application for WVE-008, targeting PNPLA3 I148M liver disease, is expected in the second half of 2026, supported by preclinical editing and liver fat reduction data.
Analysis · WVE · Life Sciences
Wave Life Sciences reported Q2 2026 financials with a net loss of $69.4 million and cash of $490.6 million, providing runway into Q3 2028. The update includes meaningful pipeline progress: dosing is underway in the Phase 2a INLIGHT trial for obesity candidate WVE-007, an FDA meeting is scheduled for end of summer 2026 to discuss accelerated approval for WVE-006 in AATD, and a CTA filing for WVE-008 is on track for 2H 2026. These milestones, combined with the cash position, reduce near-term financing risk and keep the company on track for multiple catalysts in the coming quarters.
At the time of this filing, WVE was trading at $5.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.02 to $21.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.